Details for Patent: 11,090,323
✉ Email this page to a colleague
Which drugs does patent 11,090,323 protect, and when does it expire?
Patent 11,090,323 protects SYNJARDY XR, TRIJARDY XR, GLYXAMBI, JARDIANCE, and SYNJARDY, and is included in five NDAs.
Protection for SYNJARDY XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-seven patent family members in twenty-five countries.
Summary for Patent: 11,090,323
Title: | Pharmaceutical composition, methods for treating and uses thereof |
Abstract: | The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). |
Inventor(s): | Broedl; Uli Christian (Mainz am Rhein, DE), Macha; Sreeraj (Basking Ridge, NJ), von Eynatten; Maximilian (Wiesbaden, DE), Woerle; Hans-Juergen (Grandvaux VD, CH) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
Application Number: | 16/288,192 |
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 11,090,323
International Family Members for US Patent 11,090,323
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2014247092 | ⤷ Try a Trial | |||
Canada | 2812519 | ⤷ Try a Trial | |||
Canada | 2908635 | ⤷ Try a Trial | |||
Canada | 3121761 | ⤷ Try a Trial | |||
Chile | 2015002940 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |